abrdn Healthcare Opportunities Fund Q4 2024 Commentary

2025-03-30 03:25:00 ET

Summary

• The abrdn Healthcare Opportunities Fund's equity portion fell but outperformed its custom benchmark, with Oculis Holding, Bristol-Myers Squibb, and Guardant Health as top contributors.
• Negative contributors included UnitedHealth Group, Eli Lilly, and Elevance Health, primarily due to higher medical loss ratios and drug supply constraints.
• New positions were established in Humana, Exact Sciences, and Tempus AI, while Illumina and Edwards Lifesciences were sold due to performance and growth trends.
• Despite short-term underperformance, the long-term outlook for healthcare remains favorable, supported by demographic trends and the sector's defensive characteristics.

Fund performance

Read the full article on Seeking Alpha

For further details see: